Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy
Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...
Saved in:
Main Authors: | Shota Kaburaki (Author), Naoko Okada (Author), Toru Tanaka (Author), Koichiro Kamio (Author), Yosuke Tanaka (Author), Yasuhiro Terasaki (Author), Kazuo Kasahara (Author), Masahiro Seike (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Usefulness of Transbronchial Cryobiopsy in Interstitial Lung Disease
by: Umair A Gauhar
Published: (2017) -
Concordance between sequential transbronchial lung cryobiopsy and surgical lung biopsy in patients with diffuse interstitial lung disease
by: Yoshiaki Zaizen, et al.
Published: (2019) -
Morphometrical analysis of transbronchial cryobiopsies
by: Blum Torsten-Gerriet, et al.
Published: (2011) -
Active pulmonary interstitial fibrosis in a COVID-19 survivor diagnosed by transbronchial lung cryobiopsy six months after onset
by: Yutaka Muto, et al.
Published: (2022) -
Switching to ixekizumab improves adalimumab‐induced interstitial lung disease in patients with psoriatic arthritis: A case report
by: Hideki Hayashi, et al.
Published: (2021)